Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: Living upto expectations - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 26, 2004

    Cipla: Living upto expectations

    Performance summary
    Domestic pharma major, Cipla, declared its 2QFY05 and 1HFY05 results. The topline grew by 29% in the quarter led by a good performance in both formulation exports as well as in the domestic pharma market. The bottomline has grown by 38%, which was basically due to expansion of margins.

    (Rs m) 2QFY04 2QFY05 Change 1HFY04 1HFY05 Change
    Net sales 4,512 5,814 28.8% 8,774 11,108 26.6%
    Expenditure 3,617 4,495 24.3% 7,006 8,722 24.5%
    Operating profit (EBDITA) 895 1,319 47.4% 1,768 2,386 34.9%
    Operating profit margin (%) 19.8% 22.7%   20.2% 21.5%  
    Other income 80 74 -7.6% 147 193 31.3%
    Interest 19 40 110.1% 29 53 85.4%
    Depreciation 88 125 42.9% 175 255 45.7%
    Profit before tax 869 1,229 41.4% 1,712 2,271 32.7%
    Tax 174 270 55.2% 345 520 50.7%
    Profit after tax/(loss) 695 959 37.9% 1,367 1,751 28.1%
    Net profit margin (%) 15.4% 16.5%   15.6% 15.8%  
    No. of shares (m) 300.0 300.0   300.0 300.0  
    Diluted earnings per share (Rs)* 9.3 12.8   9.1 11.7  
    P/E ratio (x)         22.8  
    (* annualised)            

    What’s the company’s business?
    Cipla is the largest pharma company in the retail market according to the latest ORG survey. The company has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by the US FDA and the formulation facilities have been approved by the Medicine Control Agency - UK, the Medicine Control Council - South Africa, the Therapeutic Goods Administration - Australia and other international agencies. On exports front, the company has strategic alliance with major generic manufactures such as Watson, Mylan, Barr and Ivax for supply of bulk drugs. It has a very wide product range in domestic market, which includes antibiotics, anti-bacterial, anti-asthmatics, anti-inflammatory, antiretroviral, anthelminites, anti-cancer and cardiovascular. In domestic formulation market, antibiotics are the mainstays. It also concentrates on developing specialty bulk drugs for export markets.

    Business snapshot
      2QFY04 2QFY05 % change
    Domestic 2,908 3,633 24.9%
    Formulations 896 1,579 76.3%
    APIs 940 838 -10.9%
    Total exports 1,836 2,417 31.6%
    Total sales 4,745 6,050 27.5%
    Other operating income      
    Technology knowhow/fees 25 97 285.7%
    Others 69 64 -6.4%
    Total 94 162 71.9%
    Total income from operations 4,839 6,212 28.4%

    What has driven performance in 1QFY05?
    Outperforms the domestic market:  Sales in the domestic market grew by 25%, thus beating the domestic market growth of 7.5% by quite a margin. Export of formulations has increased by 76%, led by higher contribution from the European and some non-regulated markets. However, supply of API's has shown decline of 10% in 2QFY05 basically due to lower API supply to the regulated markets. Exports now contribute 39% to the company’s revenues (36% in the same quarter last year).

    Operating margin expands:  Good growth in the topline helped the company to expand margins. The benefits from economies of scale were visible with lower raw material cost and lower staff cost as a percentage of sales. Also, better product and marketing mix, helped company to expand its margin by 290 basis points.

    Cost break-up
      2QFY04 2QFY05 Change
    Raw Material 2,331 2,938 26.0%
    (as % of sales) 51.7% 50.5%  
    Staff Cost 220 262 19.4%
    (as % of sales) 4.9% 4.5%  
    Other Expenditure 1,067 1,295 21.4%
    (as % of sales) 23.6% 22.3%  
    Total 3,617 4,495 24.3%

    Higher depreciation charges subdues net margin:  The profit growth would have been higher but for higher depreciation charges (owing to newly established facilities) and lower export benefits (due to withdrawal of exports benefits), which increased the tax outgo by 55%. However, the other income component has come down, as the company has invested in expanding capacity from the surplus cash reserves.

    What to expect?
    At Rs 266, the stock is trading at a price to earnings multiple of 22.8 times annualised 1HFY05 earnings. Cipla, being a dominant player in the Indian pharmaceutical industry, is likely to gain from better domestic market opportunities. Apart from this, exports will give the extra kicker to growth, once it API exports to the company's generics partners in the US increases. Being one of the most efficient producers of bulk drugs, Cipla is likely to maintain margins in the international markets, where it has adopted a low risk strategy of supplying bulk drugs to generic companies like Ivax and Watson. Overall, the results are in line with our full year estimates.



    Equitymaster requests your view! Post a comment on "Cipla: Living upto expectations". Click here!


    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 22, 2017 (Close)



    Detailed Quarterly Results With Charts